Cargando…

A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania

Background: Cannabis use is increasing among adults to treat a variety of health conditions. Given the potential for interactions and adverse events, it is important to assess the use of medical cannabis along with other concomitant medications when assessing for polypharmacy. Methods: The objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajjar, Emily R., Herens, Allison, Kelly, Erin L., Madden, Kayla, Lungen, Jessica M., Worster, Brooke K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855524/
https://www.ncbi.nlm.nih.gov/pubmed/36672666
http://dx.doi.org/10.3390/biomedicines11010158
_version_ 1784873400654626816
author Hajjar, Emily R.
Herens, Allison
Kelly, Erin L.
Madden, Kayla
Lungen, Jessica M.
Worster, Brooke K.
author_facet Hajjar, Emily R.
Herens, Allison
Kelly, Erin L.
Madden, Kayla
Lungen, Jessica M.
Worster, Brooke K.
author_sort Hajjar, Emily R.
collection PubMed
description Background: Cannabis use is increasing among adults to treat a variety of health conditions. Given the potential for interactions and adverse events, it is important to assess the use of medical cannabis along with other concomitant medications when assessing for polypharmacy. Methods: The objective of this observational, longitudinal study was to examine medical cannabis (MC) use along with concomitant medications over 12 months in patients with serious medical conditions enrolled in the Pennsylvania (PA) Department of Health’s (DOH) Medical Marijuana Program and to collect and catalog which forms of MC patients are taking along with their concomitant medications. Results: There were 213 participants who completed the baseline surveys in full, and 201, 187, and 175 who completed the 1, 6, and 12-month follow-up surveys. The mean age of the participants was 41.3 years, and 54.5% were female. The mean number of MC products taken at baseline was 3.41 and 3.47 at the 12-month survey. Participants took an average of 3.76 (SD 3.15) medications at baseline and 3.65 (SD 3.4) at 12 months. Most commonly used concomitant medications at baseline included vitamins (42.3%), antidepressants (29.1%), analgesics (22.1%), herbal products (19.7%), and anxiolytics (17.8%). Conclusion: Participants used multiple medical cannabis products to treat a number of medication conditions in conjunction with multiple medications.
format Online
Article
Text
id pubmed-9855524
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98555242023-01-21 A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania Hajjar, Emily R. Herens, Allison Kelly, Erin L. Madden, Kayla Lungen, Jessica M. Worster, Brooke K. Biomedicines Article Background: Cannabis use is increasing among adults to treat a variety of health conditions. Given the potential for interactions and adverse events, it is important to assess the use of medical cannabis along with other concomitant medications when assessing for polypharmacy. Methods: The objective of this observational, longitudinal study was to examine medical cannabis (MC) use along with concomitant medications over 12 months in patients with serious medical conditions enrolled in the Pennsylvania (PA) Department of Health’s (DOH) Medical Marijuana Program and to collect and catalog which forms of MC patients are taking along with their concomitant medications. Results: There were 213 participants who completed the baseline surveys in full, and 201, 187, and 175 who completed the 1, 6, and 12-month follow-up surveys. The mean age of the participants was 41.3 years, and 54.5% were female. The mean number of MC products taken at baseline was 3.41 and 3.47 at the 12-month survey. Participants took an average of 3.76 (SD 3.15) medications at baseline and 3.65 (SD 3.4) at 12 months. Most commonly used concomitant medications at baseline included vitamins (42.3%), antidepressants (29.1%), analgesics (22.1%), herbal products (19.7%), and anxiolytics (17.8%). Conclusion: Participants used multiple medical cannabis products to treat a number of medication conditions in conjunction with multiple medications. MDPI 2023-01-08 /pmc/articles/PMC9855524/ /pubmed/36672666 http://dx.doi.org/10.3390/biomedicines11010158 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hajjar, Emily R.
Herens, Allison
Kelly, Erin L.
Madden, Kayla
Lungen, Jessica M.
Worster, Brooke K.
A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania
title A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania
title_full A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania
title_fullStr A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania
title_full_unstemmed A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania
title_short A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania
title_sort longitudinal observational study of medical cannabis use and polypharmacy among patients presenting to dispensaries in pennsylvania
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855524/
https://www.ncbi.nlm.nih.gov/pubmed/36672666
http://dx.doi.org/10.3390/biomedicines11010158
work_keys_str_mv AT hajjaremilyr alongitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania
AT herensallison alongitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania
AT kellyerinl alongitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania
AT maddenkayla alongitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania
AT lungenjessicam alongitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania
AT worsterbrookek alongitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania
AT hajjaremilyr longitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania
AT herensallison longitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania
AT kellyerinl longitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania
AT maddenkayla longitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania
AT lungenjessicam longitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania
AT worsterbrookek longitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania